JP2007500176A - 医薬組成物 - Google Patents

医薬組成物 Download PDF

Info

Publication number
JP2007500176A
JP2007500176A JP2006521656A JP2006521656A JP2007500176A JP 2007500176 A JP2007500176 A JP 2007500176A JP 2006521656 A JP2006521656 A JP 2006521656A JP 2006521656 A JP2006521656 A JP 2006521656A JP 2007500176 A JP2007500176 A JP 2007500176A
Authority
JP
Japan
Prior art keywords
drug
water
acid
soluble
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006521656A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007500176A5 (enExample
Inventor
ベイトマン，ニコラ・フランセス
ジェラート，ポール・リチャード
デ・マタス，マーセル
ポッツ，アリソン・マーガレット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2007500176A publication Critical patent/JP2007500176A/ja
Publication of JP2007500176A5 publication Critical patent/JP2007500176A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2006521656A 2003-07-29 2004-07-27 医薬組成物 Pending JP2007500176A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0317663.3A GB0317663D0 (en) 2003-07-29 2003-07-29 Pharmaceutical composition
PCT/GB2004/003241 WO2005011647A2 (en) 2003-07-29 2004-07-27 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
JP2007500176A true JP2007500176A (ja) 2007-01-11
JP2007500176A5 JP2007500176A5 (enExample) 2007-08-16

Family

ID=27799353

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006521656A Pending JP2007500176A (ja) 2003-07-29 2004-07-27 医薬組成物

Country Status (5)

Country Link
US (1) US20070141141A1 (enExample)
EP (1) EP1651233A2 (enExample)
JP (1) JP2007500176A (enExample)
GB (1) GB0317663D0 (enExample)
WO (1) WO2005011647A2 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011513498A (ja) * 2008-03-12 2011-04-28 ユーランド，インコーポレイテッド 弱塩基性薬物と有機酸とを含む薬物送達システム
JP2011217661A (ja) * 2010-04-08 2011-11-04 Miiru Japan:Kk プロポリス組成物
JP2017002034A (ja) * 2015-06-04 2017-01-05 ファイザー・インク パルボシクリブの固形剤形
WO2017115746A1 (ja) * 2015-12-28 2017-07-06 沢井製薬株式会社 ゲフィチニブ含有錠剤
WO2019245031A1 (ja) * 2018-06-22 2019-12-26 クオリカプス株式会社 腸溶性硬質カプセル
US12214084B2 (en) 2017-07-11 2025-02-04 Qualicaps Co., Ltd. Enteric hard capsule

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2089003A1 (en) * 2006-11-09 2009-08-19 Abbott GmbH & Co. KG Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
EP1920767A1 (en) * 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
JP5382334B2 (ja) * 2008-09-19 2014-01-08 ブラザー工業株式会社 インクジェット記録用水性インクおよび水性インクセット
EP2512434B1 (en) * 2009-12-16 2016-11-16 Dow Global Technologies LLC Sunscreen compositions incorporating methylcellulose as an spf and/or ppd booster and methods
WO2012023024A2 (en) * 2010-08-17 2012-02-23 Lupin Limited Controlled release formulations of dronedarone
WO2016096999A1 (en) 2014-12-19 2016-06-23 Synthon B.V. Pharmaceutical composition comprising gefifinib
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
WO2017223018A1 (en) * 2016-06-23 2017-12-28 Dow Global Technologies Llc Esterified cellulose ethers comprising trimellityl groups
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11504033A (ja) * 1995-04-27 1999-04-06 ゼネカ リミテッド キナゾリン誘導体
WO2003032956A1 (en) * 2001-10-11 2003-04-24 Pfizer Limited Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) quinazoline
JP2005523293A (ja) * 2002-02-26 2005-08-04 アストラゼネカ アクチボラグ 水溶性セルロース誘導体を含むイレッサの医薬製剤

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3608063A (en) * 1969-08-15 1971-09-21 Gilbert S Banker Molecular drug entrapment process and compositions
US4178376A (en) * 1977-01-21 1979-12-11 Interx Research Corporation Method for inducing rapid therapeutically effective antimalarial levels of certain selected conventional antimalarials
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
US4704284A (en) * 1982-08-12 1987-11-03 Pfizer Inc. Long-acting matrix tablet formulations
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9207988D0 (en) * 1992-04-10 1992-05-27 Smithkline Beecham Plc Topical composition
AU5171293A (en) * 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
CA2164344C (en) * 1993-08-30 2004-06-29 Stanley Lech Tablet coating based on a melt-spun mixture of a saccharide and a polymer
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
ES2109796T3 (es) * 1994-05-03 1998-01-16 Ciba Geigy Ag Derivados de pirrolopirimidilo con efecto antiproliferante.
ATE554750T1 (de) * 1997-03-05 2012-05-15 Sugen Inc Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen
ATE364374T1 (de) * 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
DE19911509A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
NZ527585A (en) * 2001-02-15 2005-04-29 Tanabe Seiyaku Co Tablets quickly disintegrated in oral cavity
KR100397792B1 (ko) * 2001-06-28 2003-09-13 한국과학기술연구원 4-(페닐아미노)-[1,4]디옥사노[2,3-ｇ]퀴나졸린 유도체 및그의 제조방법
CA2477350C (en) * 2002-02-26 2013-02-12 Astrazeneca Ab Novel crystalline forms of the anti-cancer compound zd1839

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11504033A (ja) * 1995-04-27 1999-04-06 ゼネカ リミテッド キナゾリン誘導体
WO2003032956A1 (en) * 2001-10-11 2003-04-24 Pfizer Limited Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) quinazoline
JP2005523293A (ja) * 2002-02-26 2005-08-04 アストラゼネカ アクチボラグ 水溶性セルロース誘導体を含むイレッサの医薬製剤

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011513498A (ja) * 2008-03-12 2011-04-28 ユーランド，インコーポレイテッド 弱塩基性薬物と有機酸とを含む薬物送達システム
JP2011217661A (ja) * 2010-04-08 2011-11-04 Miiru Japan:Kk プロポリス組成物
JP2017002034A (ja) * 2015-06-04 2017-01-05 ファイザー・インク パルボシクリブの固形剤形
JP7627302B2 (ja) 2015-06-04 2025-02-05 ファイザー・インク パルボシクリブの固形剤形
JP2021167343A (ja) * 2015-06-04 2021-10-21 ファイザー・インク パルボシクリブの固形剤形
JP2023112149A (ja) * 2015-06-04 2023-08-10 ファイザー・インク パルボシクリブの固形剤形
WO2017115746A1 (ja) * 2015-12-28 2017-07-06 沢井製薬株式会社 ゲフィチニブ含有錠剤
JPWO2017115746A1 (ja) * 2015-12-28 2018-10-18 沢井製薬株式会社 ゲフィチニブ含有錠剤
US12214084B2 (en) 2017-07-11 2025-02-04 Qualicaps Co., Ltd. Enteric hard capsule
JPWO2019245031A1 (ja) * 2018-06-22 2021-07-08 クオリカプス株式会社 腸溶性硬質カプセル
JP7366893B2 (ja) 2018-06-22 2023-10-23 クオリカプス株式会社 腸溶性硬質カプセル
WO2019245031A1 (ja) * 2018-06-22 2019-12-26 クオリカプス株式会社 腸溶性硬質カプセル
US12280153B2 (en) 2018-06-22 2025-04-22 Qualicaps Co., Ltd. Enteric hard capsule

Also Published As

Publication number Publication date
WO2005011647A2 (en) 2005-02-10
WO2005011647A3 (en) 2005-07-28
US20070141141A1 (en) 2007-06-21
EP1651233A2 (en) 2006-05-03
GB0317663D0 (en) 2003-09-03

Similar Documents

Publication Publication Date Title
AU2003208444B2 (en) Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
US20250017930A1 (en) Pharmaceutical compositions comprising azd9291
JP5048871B2 (ja) キノリン誘導体含有医薬組成物
JP2007500176A (ja) 医薬組成物
ES2929730T3 (es) Dispersión sólida
CN112533608B (zh) 包含1,3,5-三嗪衍生物或其盐的固体药物组合物
ZA200406361B (en) Pharmaceutical formulation of iressa comprising a watersoluble cellulose derivative.
JP2020090484A (ja) エルロチニブを有効成分とする医薬錠剤
HK40047687B (en) Solid pharmaceutical composition containing 1,3,5-triazine derivative or salt thereof
HK1070585B (en) Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
HK1228245B (en) Pharmaceutical compositions comprising azd9291

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070626

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101213

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110915

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120124